Dr. Stephen Robert Marder, MD

Dr. Marder practices at Resnick Neuropsychiatric Hospital at UCLA in Los Angeles, California.

Dr. Marder's NPI, 1063437762, was assigned on July 13, 2006. Dr. Marder graduated from Jacobs School of Medicine and Biomedical Sciences in 1971. Dr. Marder holds California license G22937.

Dr. Marder's primary practice is Resnick Neuropsychiatric Hospital at UCLA, at 150 Ucla Medical Plz, Los Angeles, CA 90024 in Los Angeles County. The practice phone is (310) 267-9308.

Dr. Marder's primary practice is Resnick Neuropsychiatric Hospital at UCLA in Los Angeles, California. Dr. Marder is also affiliated with Ronald Reagan UCLA Medical Center. The medical group on file is UCLA Health. Dmand AI also links Dr. Marder to 1 more hospital and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Marder practices, 3 sites in all. Vendor and product names are available with a free account.

Psychiatry is Dr. Marder's primary specialty in the NPI Registry, under taxonomy code 2084P0800X. Dr. Marder is board certified in psychiatry by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Marder's licenses on file in 2 states: California and Maryland.

Dmand AI lists anxiety, bipolar disorder, intellectual and developmental disabilities and schizophrenia among the conditions Dr. Marder treats.

CMS data shows 137 Medicare services from Dr. Marder across 1 procedure code in 2024, all of them office visits, for 90 Medicare patients. Medicare paid $12,801 for them. Every service was in an office.

CMS counts 90 Medicare patients who saw Dr. Marder in 2024. The largest group is under 65, with 70 patients. 75% of them have schizophrenia and other psychoses, and 62% have high cholesterol. 84% are also on Medicaid. Their average risk score is 1.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Marder's median patient age at 36, with 32% women.

In 2024, Dr. Marder wrote 80 Medicare Part D claims for 11 patients. 95% of them were for generic drugs. CMS names the drug for 43 of them, across 2 drugs with 11 or more claims each, at $698 in total drug cost. In 2023, CMS named 48 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Marder for performance year 2024, reported as part of a group. Dr. Marder accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Marder as offering telehealth.

Dmand AI links 62 papers to Dr. Marder, published from 2002 to 2021. 2013 was the busiest year, with 9. Dr. Marder's most frequent co-authors are Robert W. Buchanan, MD, Christoph Correll, MD and Peter F. Buckley, MD.

Dmand AI links Dr. Marder to 13 clinical trials, 4 of them phase 2 studies. Conditions studied include Schizophrenia, Schizophrenia Spectrum and Other Psychotic Disorders and Psychotic Disorders. VA Greater Los Angeles Healthcare System sponsors the most, 4.

CMS Open Payments shows 171 general payments to Dr. Marder from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 61% of the total. Boehringer Ingelheim USA, Inc. paid the most, $32,876. It also lists 4 research payments totaling $5,987 in 2019.

Dmand AI lists 4 awards for Dr. Marder, most recently America's Top Doctors in 2014.

Dr. Marder graduated from Jacobs School of Medicine and Biomedical Sciences in 1971.

Dr. Marder is in network with 6 carriers, including Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Massachusetts and HCSC. Medicare plans come from the most carriers, 6. Check the plan with the practice before a visit.